Dipexium Pharmaceuticalsが日本のLocilex(R)特許発行を発表

AsiaNet 63894 （0381）

【ニューヨーク2016年3月28日PR Newswire＝共同通信JBN】後期段階医薬品会社で、薬効範囲の広い新局所抗微生物ペプチド、Locilex（R）（一般名ペキシガナン・クリーム0.8%）の開発、商業化に集中しているDipexium Pharmaceuticals, Inc. （Nasdaq: DPRX）は28日、日本政府がLocilexの特許を発行したと発表した。特許クレームは局所クリームとして配合された抗微生物ペプチドであるLocilexの新たな配合を対象にしている。発行された特許は2033年6月が期限である。

Dipexiumのデービッド・P・ルーシ社長兼最高経営責任者（CEO）は「世界第3の医薬品市場である日本でLocilexの特許を受けられたのはうれしい。わが社はその他の主要国際市場で追加的なLocilex特許が発行されることを期待しており、それによって全世界でLocilexの商業的実行可能性を確立し続けることが可能になる」と述べた。

▽Dipexium Pharmaceuticals, Inc.について

Dipexium Pharmaceuticals, Inc. （NASDAQ: DPRX）は後期段階医薬品会社で、薬効範囲の広い新局所抗微生物ペプチド、Locilex（一般名ペキシガナン・クリーム0.8%）の開発、商業化に集中している。当初、Locilexは軽度に化のうした糖尿病性足部潰瘍の治療を標的としていた。また入手可能な臨床、微生物学的データのまとめに基づいて、Locilexは化のうした床ずれ、やけど、手術の傷、メチシリン耐性黄色ブドウ球菌（MRSA）の鼻への広がりを含むその他の軽度から中程度の皮膚および皮膚組織の化のうを治療するための有望な製品候補ともみられている。

▽問い合わせ先

David P. Luci

President & Chief Executive Officer

Dipexium Pharmaceuticals, Inc.

+1-212-269-2834

info@dipexium.com

David Garrett

Vice President

Finance & Corporate Development

Dipexium Pharmaceuticals, Inc.

+1-212-269-2834

info@dipexium.com

(c) 2016 Dipexium Pharmaceuticals, Inc.

ソース：Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals Announces Issuance of Locilex(R) Patent in Japan

PR63894

NEW YORK, Mar. 28, 2016 /PRNewswire=KYODO JBN/--

   Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical

company focused on the development and commercialization of Locilex(R)

(pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide,

today announced that the government of Japan has issued a Locilex patent. The

patent claims are directed to a novel formulation of Locilex, an antimicrobial

peptide formulated as a topical cream. The issued patent has an expiry date in

June 2033.

   "We are delighted to receive a Locilex patent in Japan, the third largest

pharmaceuticals market in the world," stated David P. Luci, President & Chief

Executive Officer of Dipexium, "We anticipate the issuance of additional

Locilex patents in other major international markets which will allow us to

continue to establish commercial viability of Locilex throughout the world."

   About Dipexium Pharmaceuticals, Inc.

   Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical

company focused on the development and commercialization of Locilex(R)

(pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide.

Initially, Locilex is targeted for the treatment of mild infections of diabetic

foot ulcers. Based on a compilation of available clinical and microbiology

data, Locilex is also considered a promising product candidate to treat other

mild and moderate skin and skin structure infections, including infected

decubitus ulcers, infected burns, infected surgical wounds and nasal

colonization of methicillin-resistant staphylococcus aureus (MRSA).

   Cautionary Note on Forward-Looking Statements

   This press release and any statements of representatives and partners of

Dipexium Pharmaceuticals, Inc. (the "Company") related thereto contain, or may

contain, among other things, certain "forward-looking statements" within the

meaning of the U.S. federal securities laws.  Such forward-looking statements

involve significant risks and uncertainties. Such statements may include,

without limitation, statements with respect to the Company's plans, objectives,

projections, expectations and intentions and other statements identified by

words such as "projects," "may," "will," "could," "would," "should,"

"believes," "expects," "anticipates," "estimates," "intends," "plans,"

"potential" or similar expressions. These statements are based upon the current

beliefs and expectations of the Company's management and are subject to

significant risks and uncertainties, including those detailed in the Company's

filings with the Securities and Exchange Commission and those that relate to

the Company's ability to leverage the expertise of employees and partners to

assist the Company in the execution of its strategy. Actual results (including,

without limitation, the timing for and results of the clinical trials and

proposed NDA submission for Locilex(R)) may differ significantly from those set

forth in the forward-looking statements. These forward-looking statements

involve certain risks and uncertainties that are subject to change based on

various factors (many of which are beyond the Company's control). The Company

undertakes no obligation to publicly update any forward-looking statements,

whether as a result of new information, future events or otherwise, except as

required by applicable law.

   Company Contacts:

   David P. Luci

   President & Chief Executive Officer

   Dipexium Pharmaceuticals, Inc.

   +1-212-269-2834

   info@dipexium.com;

   David Garrett

   Vice President

   Finance & Corporate Development

   Dipexium Pharmaceuticals, Inc.

   +1-212-269-2834

   info@dipexium.com

   (c) 2016 Dipexium Pharmaceuticals, Inc.  All rights reserved.

   SOURCE: Dipexium Pharmaceuticals, Inc.